Home > Publications Database > A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease. > print

001     277883
005     20250504001132.0
024 7 _ |a 10.1038/s41531-025-00885-5
|2 doi
024 7 _ |a pmid:40180909
|2 pmid
024 7 _ |a pmc:PMC11968880
|2 pmc
024 7 _ |a altmetric:175822277
|2 altmetric
037 _ _ |a DZNE-2025-00503
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bedarf, Janis
|0 P:(DE-2719)2811747
|b 0
|e First author
245 _ _ |a A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745915661_11441
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Current treatment of Parkinson's Disease (PD) remains symptomatic, and disease-modifying approaches are urgently required. A promising approach is to modify intestinal microbiota and key metabolites of bacterial fermentation: short-chain fatty acids (SCFA), which are decreased in PD. A prospective, controlled pilot study (DRKS00034528) was conducted on 11 couples (PD patient plus healthy spouse as control (CO)). Participants followed a 4-week diet rich in dietary fibre, including intake of the prebiotic Lactulose. Gut metagenomes, faecal and urinary metabolites, and clinical characteristics were assessed. The dietary intervention significantly augmented faecal SCFA and increased Bifidobacteria spp., reducing PD-related gastrointestinal symptoms. The pre-existing bacterial dysbiosis in PD (depletion of Blautia, Dorea, Erysipelatoclostridium) persisted. Bacterial metabolite composition in faeces and urine positively changed with the intervention: Brain-relevant gut metabolic functions involved in neuroprotective and antioxidant pathways, including S-adenosyl methionine, glutathione, and inositol, improved in PD. These promising results warrant further investigation in larger cohorts.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Romano, Stefano
|0 0000-0002-7600-1953
|b 1
700 1 _ |a Heinzmann, Silke Sophie
|b 2
700 1 _ |a Duncan, Anthony
|0 0000-0002-3849-9527
|b 3
700 1 _ |a Traka, Maria H
|b 4
700 1 _ |a Ng, Duncan
|b 5
700 1 _ |a Segovia-Lizano, Daniella
|b 6
700 1 _ |a Simon, Marie-Christine
|b 7
700 1 _ |a Narbad, Arjan
|b 8
700 1 _ |a Wüllner, Ullrich
|0 P:(DE-2719)2000056
|b 9
|u dzne
700 1 _ |a Hildebrand, Falk
|b 10
773 _ _ |a 10.1038/s41531-025-00885-5
|g Vol. 11, no. 1, p. 66
|0 PERI:(DE-600)2819218-7
|n 1
|p 66
|t npj Parkinson's Disease
|v 11
|y 2025
|x 2373-8057
856 4 _ |u https://pub.dzne.de/record/277883/files/DZNE-2025-00503%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277883/files/DZNE-2025-00503.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/277883/files/DZNE-2025-00503%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277883/files/DZNE-2025-00503.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277883
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811747
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000056
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner
|l Biomarker Parkinson's Disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011302
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21